Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Male and female, ages 18 to 70 years~* Diagnosis of plaque psoriasis for 6 months~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy~* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the study drug plus 90 days.~Exclusion Criteria:~* Any significant acute or chronic medical illness~* Blood transfusion within 4 weeks of study drug administration~* Inability to tolerate oral medication~* Positive hepatitis-B (HBV) surface antigen~* Positive hepatitis-C (HCV) antibody~* Any history or risk for tuberculosis (TB)~* Any major illness/condition or evidence of an unstable clinical condition~* Chest X-ray findings suspicious of infection at screening~* has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication~* Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first administration of study medication~* Has received Rituximab within 6 months of first administration of study medication~* Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication~* Any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BMS-986165 Dose 1 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 2 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 3 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 4 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- BMS-986165 Dose 5 (Type: EXPERIMENTAL): Specified dose of BMS-986165 on specified days.
- Placebo (Type: PLACEBO_COMPARATOR): Specified dose of Placebo for BMS-986165 on specified days.

Based on this trial design, predict the completion outcome and termination type (if applicable).